Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Anemia Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Anemia 15
Anemia Therapeutics under Development by Companies 17
Anemia Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Anemia Therapeutics - Products under Development by Companies 31
Anemia Therapeutics - Products under Investigation by Universities/Institutes 37
Companies Involved in Anemia Therapeutics Development 47
Genzyme Corporation 47
Hospira, Inc. 47
F. Hoffmann-La Roche Ltd. 48
Medgenics Inc. 48
Medinox, Inc. 49
Amgen Inc. 49
Eli Lilly and Company 50
GlaxoSmithKline plc 50
Inovio Biomedical Corporation 51
Green Cross Corporation 63
Hanall Pharmaceutical Co., Ltd. 64
LG Life Sciences, Ltd 64
Affymax, Inc. 65
Acceleron Pharma, Inc. 65
Pieris AG 66
Xenon Pharmaceuticals Inc. 66
ERYtech Pharma 67
Archemix Corp. 67
NormOxys, Inc. 68
HemaQuest Pharmaceuticals, Inc. 68
Akebia Therapeutics, Inc. 69
GENETIX Pharmaceuticals, Inc. 69
Selexys Pharmaceuticals Corporation 70
Genexine Co., Ltd. 70
NOXXON Pharma AG 71
Morphogenesis, Inc. 71
Bolder Biotechnology, Inc. 72
Palkion, Inc. 72
Galileo Pharmaceuticals, Inc. 73
Emmaus Medical, Inc. 73
Discovery Genomics, Inc. 74
Bellicum Pharmaceuticals, Inc. 74
GlycoMimetics, Inc. 75
Avesthagen Limited 75
PharmaEssentia Corporation 76
AesRx, LLC. 76
Helix Therapeutics LLC 77
Errant Gene Therapeutics, LLC 77
Anemia - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Route of Administration 80
Assessment by Molecule Type 83
Late Stage Drug Profiles 86
Aranesp - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Peginesatide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Peginesatide - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
R744 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Soliris - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Feraheme - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
PselmabG1 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SFP-Hemodialysis - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Ferinject + Erythropoietin - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
Nascobal - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
Anemia Therapeutics – Drug Profile Updates 161
Anemia Therapeutics - Discontinued Products 167
Anemia - Featured News 169
Sep 23, 2011: Alexion Receives FDA Approval For Soliris In Atypical Hemolytic Uremic Syndrome 169
Sep 23, 2011: Alexion Receives Positive Opinion From CHMP For Soliris In Patients With Atypical Hemolytic Uremic Syndrome 170
Sep 19, 2011: FerroKin BioSciences Starts Phase II Clinical Trial Of FBS0701 As New Oral Treatment For Transfusional Iron Overload In Pediatric Population 170
Sep 19, 2011: FerroKin BioSciences Starts Phase II Clinical Trial Of FBS0701 As New Oral Treatment For Transfusional Iron Overload In Pediatric Population 171
Sep 19, 2011: FerroKin BioSciences Starts Phase II Clinical Trial Of FBS0701 As New Oral Treatment For Transfusional Iron Overload In Pediatric Population 171
Sep 14, 2011: ApoPharma Announces FDA Advisory Committee Recommendation In Favor Of Ferriprox Approval 172
Sep 13, 2011: Acceleron Initiates Phase I Study Of ACE-536 In Anemia 172
Sep 12, 2011: HemaQuest Completes Enrollment In Phase II Clinical Study Of HQK-1001 In Patients With Sickle Cell Disease 173
Sep 06, 2011: Hospira Announces Positive Results From Phase I US Clinical Trial Of Biosimilar Erythropoietin In Renal Patients 173
Sep 06, 2011: NOXXON Initiates Phase I Clinical Trial Of NOX-H94 For Anemia Of Chronic Disease 174
Appendix 175
Methodology 175
Coverage 175
Secondary Research 175
Primary Research 175
Expert Panel Validation 176
Contact Us 176
Disclaimer 176
List of Tables
Number of Products Under Development for Anemia, H2 2011 15
Products under Development for Anemia – Comparative Analysis, H2 2011 16
Number of Products under Development by Companies, H2 2011 18
Number of Products under Development by Companies, H2 2011 19
Number of Products under Development by Companies, H2 2011 20
Number of Products under Investigation by Universities/Institutes, H2 2011 22
Number of Products under Investigation by Universities/Institutes, H2 2011 23
Number of Products under Investigation by Universities/Institutes, H2 2011 24
Number of Products under Investigation by Universities/Institutes, H2 2011 25
Number of Products under Investigation by Universities/Institutes, H2 2011 26
Comparative Analysis by Late Stage Development, H2 2011 27
Comparative Analysis by Mid Clinical Stage Development, H2 2011 28
Comparative Analysis by Early Clinical Stage Development, H2 2011 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011 30
Products under Development by Companies, H2 2011 31
Products under Development by Companies, H2 2011 32
Products under Development by Companies, H2 2011 33
Products under Development by Companies, H2 2011 34
Products under Development by Companies, H2 2011 35
Products under Development by Companies, H2 2011 36
Products under Investigation by Universities/Institutes, H2 2011 37
Products under Investigation by Universities/Institutes, H2 2011 38
Products under Investigation by Universities/Institutes, H2 2011 39
Products under Investigation by Universities/Institutes, H2 2011 40
Products under Investigation by Universities/Institutes, H2 2011 41
Products under Investigation by Universities/Institutes, H2 2011 42
Products under Investigation by Universities/Institutes, H2 2011 43
Products under Investigation by Universities/Institutes, H2 2011 44
Products under Investigation by Universities/Institutes, H2 2011 45
Products under Investigation by Universities/Institutes, H2 2011 46
Genzyme Corporation, H2 2011 47
Hospira, Inc., H2 2011 47
F. Hoffmann-La Roche Ltd., H2 2011 48
Medgenics Inc., H2 2011 48
Medinox, Inc., H2 2011 49
Amgen Inc., H2 2011 49
Eli Lilly and Company, H2 2011 50
GlaxoSmithKline plc, H2 2011 50
Inovio Biomedical Corporation, H2 2011 51
Rockwell Medical Technologies, Inc., H2 2011 51
Apotex, Inc., H2 2011 52
Merck & Co., Inc., H2 2011 52
United Biomedical, Inc., H2 2011 53
Sangamo BioSciences, Inc., H2 2011 53
FibroGen, Inc., H2 2011 54
Novartis AG, H2 2011 54
BioMarin Pharmaceutical Inc., H2 2011 55
Cephalon, Inc., H2 2011 55
Galenica Ltd., H2 2011 56
Hanmi Pharmaceutical Co Ltd, H2 2011 56
Zydus Cadila Healthcare Limited, H2 2011 57
3SBio Inc., H2 2011 57
Evotec Aktiengesellschaft, H2 2011 58
Ligand Pharmaceuticals Incorporated, H2 2011 58
Ariad Pharmaceuticals, Inc., H2 2011 59
PROLOR Biotech, Inc., H2 2011 59
Biovitrum AB, H2 2011 60
Accentia Biopharmaceuticals, Inc., H2 2011 60
Alexion Pharmaceuticals, Inc., H2 2011 61
Alnylam Pharmaceuticals, Inc, H2 2011 61
ProMetic Life Sciences Inc., H2 2011 62
Lipoxen PLC, H2 2011 62
Boryung Pharmaceutical Co., Ltd., H2 2011 63
Green Cross Corporation, H2 2011 63
Hanall Pharmaceutical Co., Ltd., H2 2011 64
LG Life Sciences, Ltd, H2 2011 64
Affymax, Inc., H2 2011 65
Acceleron Pharma, Inc., H2 2011 65
Pieris AG, H2 2011 66
Xenon Pharmaceuticals Inc., H2 2011 66
ERYtech Pharma, H2 2011 67
Archemix Corp., H2 2011 67
NormOxys, Inc., H2 2011 68
HemaQuest Pharmaceuticals, Inc., H2 2011 68
Akebia Therapeutics, Inc., H2 2011 69
GENETIX Pharmaceuticals, Inc., H2 2011 69
Selexys Pharmaceuticals Corporation, H2 2011 70
Genexine Co., Ltd., H2 2011 70
NOXXON Pharma AG, H2 2011 71
Morphogenesis, Inc., H2 2011 71
Bolder Biotechnology, Inc., H2 2011 72
Palkion, Inc., H2 2011 72
Galileo Pharmaceuticals, Inc., H2 2011 73
Emmaus Medical, Inc., H2 2011 73
Discovery Genomics, Inc., H2 2011 74
Bellicum Pharmaceuticals, Inc., H2 2011 74
GlycoMimetics, Inc., H2 2011 75
Avesthagen Limited, H2 2011 75
PharmaEssentia Corporation, H2 2011 76
AesRx, LLC., H2 2011 76
Helix Therapeutics LLC, H2 2011 77
Errant Gene Therapeutics, LLC, H2 2011 77
Assessment by Monotherapy Products, H2 2011 78
Assessment by Combination Products 79
Assessment by Stage and Route of Administration, H2 2011 82
Assessment by Molecule Type, H2 2011 85
Anemia Therapeutics – Drug Profile Updates 161
Discontinued Products 167
List of Figures
Number of Products under Development for Anemia, H2 2011 15
Products under Development for Anemia – Comparative Analysis, H2 2011 16
Products under Development by Companies, H2 2011 17
Products under Investigation by Universities/Institutes, H2 2011 21
Late Stage Products, H2 2011 27
Mid Clinical Stage Products, H2 2011 28
Early Clinical Stage Products, H2 2011 29
Discovery and Pre-Clinical Stage Products, H2 2011 30
Assessment by Monotherapy Products, H2 2011 78
Assessment by Combination Products, H2 2011 79
Assessment by Route of Administration, H2 2011 80
Assessment by Stage and Route of Administration, H2 2011 81
Assessment by Molecule Type, H2 2011 83
Assessment by Stage and Molecule Type, H2 2011 84